跳至主要内容
临床试验/NCT04132687
NCT04132687Unknown不适用

To Determine the Efficacy of Autologous Blood Patch Therapy in Reducing Air Leak in Secondary Spontaneous Pneumothorax: A Proof-of-Concept Study

Chinese University of Hong Kong2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2019年9月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
35
试验地点
2
主要终点
air leak reduction

研究概览

简要总结

This is a prospective clinical trial with each patient serving as his/her own control. Patients will be recruited in three different Hong Kong hospital. All patients at the recruitment centers with ongoing air leak after ≥ 3 days from the initial diagnosis of SSP will be approached by site investigators. Patient consented to enter the study will have their rate of air leak measured on day 3 (or after if enrolled later than day 3) byreplacing the conventional chest drain system with the digital chest drainage device (Thopaz).

Autologous blood patch will be instilled if the patient still has persistent air leak on day 5 of chest drain insertion ( or 48 hours of electronic chest drain measurement of airleak).

详细描述

The patient must have a chest tube in place and checked to be patent. Approximately 1.5ml/kg of venous blood will be withdrawn from the patient and immediately instilled it into the pleural cavity with aseptic technique via the chest tube already in situ. (There is no standard amount of blood used for ABPT. A small randomized study advocated that the use of 1.5ml/kg as it provided the optimal benefits.) The drain is then flushed with 20ml normal saline to avoid clotting. The tube of the drain is immediately elevated to 60cm above the insertion point of the chest tube at the patient's chest wall for 2 hours. This method allows ongoing evacuation of any air leak while the instilled blood can stay within the pleural cavity. The tube is never clamped at any stage to avoid any risk of tension pneumothorax. The patient was asked to change his position in bed every 10 minutes (supine, right lateral, prone, left lateral, head down and sit upright) during the two-hour period to aid distribution of blood over the visceral pleura. The tube is returned to normal position after two hours and the patient is free to ambulate. Analgesia is freely available for the patient should the need arise, but will not be prescribed routinely as existing data suggest it is uncommon.

Patients will remain under close observation after the instillation for the next 6 hours by experienced respiratory doctors and nurses, in particular for any suggestion of tube blockage or worsening pneumothorax. The tube will be flushed with saline (of an amount similar to the dead space of the tube) if that occurs. In the very unlikely event that the blockage is not correctable, a new chest tube may be placed if deemed clinically necessary. Prophylactic antibiotics will be given at the discretion of the attending clinician. The amount of air leak is measured continuously before and after ABPT using Thopaz system. Patients are free to receive any other therapy (except pleurodesis) during the treatment period.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • aged 18 years or older;
  • radiographically proven pneumothorax and underlying lung disease (either pre-existing or shown in diagnostic imaging at presentation);
  • chest tube inserted which still shows an air leak at day 5 (or later) after the first radiographic evidence of a pneumothorax.

排除标准

  • inability to provide informed consent;
  • a chest tube smaller than 12 F (because of the risk of blockage by blood)
  • bilateral pneumothorax
  • uncorrectable coagulopathy
  • active or recent (within 6 weeks) pleural infection
  • use of long term steroid or immunosuppressant
  • septicaemia or active extrapleural infection (eg pneumonia)

研究组 & 干预措施

autologous blood patch

Other

autologoust blood patch therapy

干预措施: autologous blood patch therapy (Procedure)

结局指标

主要结局

air leak reduction

时间窗: 48 hours

percentage of air leak reduction after autologous blood patch

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ngai Chun Li

Principal Investigator

Chinese University of Hong Kong

研究点 (2)

Loading locations...

相似试验